An Open-Label Extension Study to Assess the Long-Term Safety And Efficacy Of Dupilumab In Patients ?6 Months To <18 Years Of Age With Atopic Dermatitis

What is the goal of the study?

This is a phase 3, open-label extension study investigating the long-term safety, efficacy, PK, and immunogenicity of repeat monthly SC doses of dupilumab in pediatric patients with AD who have previously completed a clinical study with dupilumab in patients with AD. Site For R668-AD-1434: OLE Dupilumab

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

• PI (Study Doctor): Markus Boos
• Study Team Member: Jacqueline Lee-Eng, [email protected]